행촌 (杏邨) 김상호 (金象皓) 교수 정년 기념호, 행촌 (杏邨) 김상호 (金象皓) 교수 약력 (略歷)

연구소자료 전북대학교 의과학연구소 1997 全北醫大論文集 Vol.21 No.1

N/A

증례 ( Case Reports ) : 제 6 차 전북대학교 의과대학 학술집담회 초록 : Mepirizole 유도 십이지장궤양에 관한 실험적 연구

연구소자료 전북대학교 의과학연구소 1985 全北醫大論文集 Vol.9 No.4

덕암 (德巖) 황인담 (黃仁澹) 교수 화연기념호 (花宴紀念號), 덕암 황인담 교수 약력

연구소자료 전북대학교 의과학연구소 1986 全北醫大論文集 Vol.10 No.1

N/A

21세기 새로운 시대를 준비하는 원광대학교 의과대학의 교육목표 개정과정

이학승,김요식,송윤강,오재민,양연식,정선관 원광대학교 의과학연구소 2009 圓光醫科學 Vol.24 No.1

교육목적은 대학의 교육이 지향하는 대전제이다. 그러므로 대학교육 목적과 목표가 어떤가에 따라 교육과정과 교육방법이 달라진다. 원광대학교 의과대학의 교육목표는, '지덕겸수'로 요약되는 '과학과 도학을 겸비한 전인교육'의 건학정신과 '학술탐구'와 '덕성함양'의 원광대학교 교육목표와 일치하게 현재까지 유지되었다. 그러나 현행 교육목표의 여러 문제점이 발견되었고, 시대상의 변화에 따라 원광대학교 의과대학에서도 사회적 변화 빛 의료인에 대한 시대적 요구에 걸맞은 의학교육의 목적 및 목표의 재설정 과정을 시작하게 되었다. 그 결과 개정 작업을 통해 새로운 교육목표를 설정하게 되었으며 그 내용은 다음과 같다. 1. 기본진료능력을 지닌 의사를 양성한다. 2. 원불교 교리 이념을 반영한 윤리적, 도덕적인 의사를 양성한다. 3. 평생 학습하는 연구하는 의사 혹은 의과학자를 양성한다. 4. 사회적 책무를 수행하는 리더십을 갖춘 의사를 양성한다. 5. 지역 사회에 공헌하는 봉사정신을 갖춘 의사를 양성한다. Purpose : With the changes to the medical environments and to the medical educational systems, we aimed to evaluate the current mission statement of the School of Medicine, Wonkwang University, and to revise it. Methods : To establish the new goal and mission statement, a Special Committee for the Revision of Medical School Mission and advisory group were organized in 2008. This special committee conducted through five steps of action, which are composed of investigation, education, development, surveillance of various opinions, and announcement. Results : For the development of new goal and mission, the revised, final goal and mission statements decided through the five steps of action. The new mission of Wonkwang University School of Medicine was as follows; 1. Doctor who can diagnose and treat easily 2. Ethical and moral doctor who practice Won Buddhism 3. Doctor or Medical Scholar who studies lifelong study 4. Doctor who has leadership to social responsibility 5. Doctor who goes into service to a local community. Conclusion : The authors expect that the new goal and mission of Wonkwang University School of Medicine would be helpful in giving the guideline on the educational process of medical school and will give the information to reform the medical school system according to the rapidly changing educational environment.

우보 (牛步) 하대유 (河大有) 교수 화연기념호 (花宴紀念號), 하대유 교수 약력 (略歷)

연구소자료 전북대학교 의과학연구소 1993 全北醫大論文集 Vol.17 No.1

N/A

고콜레스테롤 혈증 환자에서 Cerivastatin(LIPOBAY, 의과학연구소)의 임상효과 및 안전성에 관한 연구

박성훈,김미연,정수진,이영숙,박창한,변은경,전성희 梨花女子大學校 醫科大學 醫科學硏究所 2001 EMJ (Ewha medical journal) Vol.24 No.3

목적 : Cerivastatin(LIPOBAY)은 최근에 개발되어 사용되기 시작한 HMG-CoA 환원효소 억제제로서 저용량으로 탁월한 콜레스테롤 강하효과를 보이는 약물이다. 저자들은 Cerivatatin(LIPOBAY)의 혈중 콜레스테롤 강하효과를 평가하고 약물의 안전성을 평가하기 위하여 본 연구를 시행하였다. 방법 : 고콜레스테롤혈증 환자 37명(남자 13명, 여자 24명)을 대상으로 하였다. 대상환자는 2주간의 저콜레스테롤 식이 후에도 혈청 콜레스테롤이 240㎎/㎗이상이거나, 관상동맥질환이 있는 환자는 혈청콜레스테롤이 220㎎/㎗이상인 경우 cerivastatin 0.4㎎을 8주간 복용하도록 하였다. 임상적 관찰과 검사실 검사(간기능검사, 일반혈액검사, 혈청지질검사)는 투약개시 후 4주 및 8주 후에 시행하였다. 결과 : Cerivastatin 0.4㎎을 4주간 투여한 후 측정한 LDL 콜레스테롤, 총콜레스테롤, triglyceride, 및 HDL 콜레스테롤은 각각 38%, 28.8%, 11.6% 및 7.8% 감소하였다. 총콜레스테롤/HDL 콜레스테롤 비 및 LDL/HDL비는 각각 20.8% 및 31.1% 감소하였다. 투약 8주후에 측정한 검사소견은 4주후에 비해 유의한 변화를 보이지 않았다. 한명의 환자(2.7%)에서 간기능 검사상 AST, 및 ALT의 지속적인 상승으로 투약을 중지하였다. 결론 : Cerivastatin 0.4㎎/day는 혈청콜레스테롤을 효과적으로 감소시켰으며 심각한 부작용은 볼 수 없었다. 따라서 적극적으로 LDL콜레스테롤을 낮출 필요가 있는 고콜레스테롤혈증 환자에서 cerivastatin은 효과적이고 안전한 약물이라고 생각된다. Objectives : Cerivastain(LIPOBAY) is recently developed HMG-CoA reductase inhibitor which is effective in lowering serum cholesterol levels at microgram does. We evaluated the clinical efficacy and safety of cerivastatin(LIPOBAY) in patients with hypercholesterolemia. Method : Thirty-seven patients(male : 13, female : 24) with hypercholesteolemia defined as baseline serum total cholesterol ≥240㎎/㎗, or ≥220㎎/㎗ in patients with known coronary artery disease were included for this study. After 2 weeks of low cholesterol diet, if the serum total choesterol level meet the criteria, cerivastain 0.4㎎/day was prescribed for 8 weeks. Clinical follow-up and laboratory tests were performed 4 weeks and 8 weeks after medication. Results : After 4 weeks of cerivastain 0.4㎎/day treatment, low density lipoprotein(LDL) cholesterol decreased 38% and total cholesterol decreased 28.8% from baseline. Triglyceride decreased 11.6%, and high density lipoprotein(HDL) cholesterol decreased 7.8% from baseline. Total cholesterol/HDL ratio decreased 20.8% and LDL/HDL ratio decreased 31.1% from baseline. After 8 weeks of treatment, no further significant changes were noted compared with the values at 4 weeks. Cervastatin was discontinued in one patient(2.7%) due to continuous liver enzyme elevation. Conclusion : Cerivastatin 0.4㎎/day is effective in lowering serum cholesterol levels without significant adverse reactions. Cerivastatin is effective and safe for patients with hypercholesterolemia who needs aggressive LDL cholesterol lowering.

난소의 미성숙 기형종 1예

최기욱,김흥곤,문형배 圓光大學校 醫科學硏究所 1994 圓光醫科學 Vol.10 No.1-2

The immature teratoma is the third most commin germ cell tumor of the ovary. It contains a variable amount of immature tissue derived from the three germ cell layers-ectoderm, mesoderm and endoderm. Most commonly the immature elements are neural origin. With the usage of chemotherapy following appropriate surgery, prognosis for patient with malignant germ cell tumor was improved considerably. We had experienced a case of immature teratoma of ovary. We report the case with review of the concerned literatures.

Modulith SLX 체외충격파 쇄석기를 이용한 요석 치험 707례

임희관 圓光大學校 醫科學硏究所 1997 圓光醫科學 Vol.13 No.1-2

Purpose: We attempted to assess the results of Modulith SLX lithotripsy for management of urinary stones. Materials and methods: Between January 3, 1995 and December 31, 1996, 707 renal units in 668 patients with urinary stones were treated by extracorporeal shock wave lithotripsy (ESWL) with the Modulith SLX lithotriptor. Results: 1. The average age of patients was 49.6 years, with a range of 5 to 93 years. There were 395 male patients and 273 female patients with a ratio of sex 1.45 : 1. 2. The stones were located in the kidney (except staghorn calculi) in 160 cases (22.6%), staghorn calculi in 13 cases (1.8%), ureteropelvic junction (UPJ) in 19 cases (2.7%), upper ureter in 200 cases (28.3%), mid ureter in 34 cases (4.9%), lower ureter in 271 cases (38.3%) and bladder in 10 cases (1.4%). 3. Average treatment sessions and time (min.) were 1.8 ± 1.4 and 28.6 ± 4.2, respectively. 4. Success rates according to stone size were 99.6% in less than 1㎠, 97.2% in 1㎠ to 2㎠, 91.3% in 2㎠ to 3㎠ and 78.1% more than 3㎠. 5. Success rates according to stone location were 100% in renal stones (except staghorn calculi), 84.6% in staghorn calculi, 94.7% in UPJ stones, 98.5% in upper ureteral stones, and 98.6% in lower ureteral stones and 30% in bladder stones. 6. Complications were gross hematuria (≥3days) in 76 cases(10.7%), steinstrasse in 89 cases(12.5%), fever (≥38℃) in 16 cases(2.3%) and perirenal hematoma in 5 cases(0.7%). Conclusions: We conclude that extracorporeal shock wave lithotripsy with Modulith SLX lithotriptor is a safe and effective procedure for the treatment of urinary stones.

흉막 국균증(Pleural Aspergillosis) 치험 1례

김학렬,정은택 圓光大學校 醫科學硏究所 1997 圓光醫科學 Vol.13 No.1-2

Pleural aspergillosis is not associated with pulmonary aspergillosis. However, it could occur in patients who have a chronic pneumothorax and bronchopleural fistula with pulmonary tuberculosis history. The treatment requires a thoracoplastic operation following a pleuropneumonectomy. This procedure includes the administering of an antifungal agent such as Amphotericin B or Nystatin via parenteral or intrapleural infusion for several months. Our report includes a) a study on a patient who came to us, and was found to have aspergillosis during a microscopic examination and cultivation test of pleural discharge, and who had been diagnosed with pneumothorax, bronchopleural fistula and pulmonary tuberculosis history twelve years earlier. The patient was then given a pleural decortication prior to and following which antifungal agent was administered, b) a research of applicable literature.

진구성 아킬레스 건 파열에서 V-Y 건편(tendinous flap)을 이용한 재건술

전철홍,박근호,나범수 圓光大學校 醫科學硏究所 1991 圓光醫科學 Vol.7 No.1-2

Old ruptures of the Achilles tendon are not common, and they pose many difficult problems in which wide separation of the ruptured tendon is not repaired by end-to-end due to intervening scar tissue. Many methods have been attempted to fulfill the gap by grafting and to restore the continuity of the tendon. Although the results in many methods were reported as good or excellent, the extent of functional disability and residual muscle power were not usually unsatisfactory. We operated the 4 patients with old rupture of the Achilles tendon by end-to-end anastomosis using the V-Y tendinous flap originated by Abraham and Pankovich in 1975. The postoperative results were satisfactory with no functional disability of muscle power. There was neither re-rupture of the Achilles tendon nor adhesion of the tendon to the skin. Furthermore the skin problem is not developed. In conclusion, the V-Y tendinous flap is easy to do, and the power of triceps muscle is normal range. So we recommend that the method is useful for the treatment of old rupture of the Achilles tendon in which end-to-end anastomosis is otherwise impossible.